FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968279575> ?p ?o ?g. }

• W2968279575 endingPage "2110" @default.
• W2968279575 startingPage "2097" @default.
• W2968279575 abstract "Abstract Pancreatic cancer remains an incurable condition. Its progression is driven, in part, by subsets of cancer cells that evade the cytotoxic effects of conventional chemotherapies. These cells are often low-cycling, multidrug resistant, and adopt a stem cell–like phenotype consistent with the concept of cancer stem cells (CSC). To identify drugs impacting on tumor-promoting CSCs, we performed a differential high-throughput drug screen in pancreatic cancer cells cultured in traditional (2D) monolayers versus three-dimensional (3D) spheroids which replicate key elements of the CSC model. Among the agents capable of killing cells cultured in both formats was a 1H-benzo[d]imidazol-2-amine–based inhibitor of IL2-inducible T-cell kinase (ITK; NCGC00188382, inhibitor #1) that effectively mediated growth inhibition and induction of apoptosis in vitro, and suppressed cancer progression and metastasis formation in vivo. An examination of this agent's polypharmacology via in vitro and in situ phosphoproteomic profiling demonstrated an activity profile enriched for mediators involved in DNA damage repair. Included was a strong inhibitory potential versus the thousand-and-one amino acid kinase 3 (TAOK3), CDK7, and aurora B kinases. We found that cells grown under CSC-enriching spheroid conditions are selectively dependent on TAOK3 signaling. Loss of TAOK3 decreases colony formation, expression of stem cell markers, and sensitizes spheroids to the genotoxic effect of gemcitabine, whereas overexpression of TAOK3 increases stem cell traits including tumor initiation and metastasis formation. By inactivating multiple components of the cell-cycle machinery in concert with the downregulation of key CSC signatures, inhibitor #1 defines a distinctive strategy for targeting pancreatic cancer cell populations." @default.
• W2968279575 created "2019-08-22" @default.
• W2968279575 creator A5002699549 @default.
• W2968279575 creator A5014278257 @default.
• W2968279575 creator A5021784750 @default.
• W2968279575 creator A5023766610 @default.
• W2968279575 creator A5028439777 @default.
• W2968279575 creator A5029334844 @default.
• W2968279575 creator A5042175883 @default.
• W2968279575 creator A5046463254 @default.
• W2968279575 creator A5065979183 @default.
• W2968279575 creator A5069062997 @default.
• W2968279575 creator A5069758017 @default.
• W2968279575 creator A5075736599 @default.
• W2968279575 creator A5076591186 @default.
• W2968279575 creator A5082550776 @default.
• W2968279575 creator A5083662386 @default.
• W2968279575 creator A5088422127 @default.
• W2968279575 creator A5088710046 @default.
• W2968279575 creator A5091429263 @default.
• W2968279575 date "2019-11-01" @default.
• W2968279575 modified "2023-09-30" @default.
• W2968279575 title "Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype" @default.
• W2968279575 cites W1717645955 @default.
• W2968279575 cites W1968812902 @default.
• W2968279575 cites W1972724690 @default.
• W2968279575 cites W1972821149 @default.
• W2968279575 cites W1979964863 @default.
• W2968279575 cites W1985535740 @default.
• W2968279575 cites W1996694381 @default.
• W2968279575 cites W2002143632 @default.
• W2968279575 cites W2004878973 @default.
• W2968279575 cites W2007253892 @default.
• W2968279575 cites W2009397177 @default.
• W2968279575 cites W2017753146 @default.
• W2968279575 cites W2018667790 @default.
• W2968279575 cites W2019264784 @default.
• W2968279575 cites W2033591223 @default.
• W2968279575 cites W2039753443 @default.
• W2968279575 cites W2045000546 @default.
• W2968279575 cites W2049651125 @default.
• W2968279575 cites W2049876223 @default.
• W2968279575 cites W2055624262 @default.
• W2968279575 cites W2058097237 @default.
• W2968279575 cites W2060551076 @default.
• W2968279575 cites W2071123870 @default.
• W2968279575 cites W2072693879 @default.
• W2968279575 cites W2074956041 @default.
• W2968279575 cites W2079012552 @default.
• W2968279575 cites W2096969612 @default.
• W2968279575 cites W2113871357 @default.
• W2968279575 cites W2120656656 @default.
• W2968279575 cites W2131170195 @default.
• W2968279575 cites W2131928488 @default.
• W2968279575 cites W2140152239 @default.
• W2968279575 cites W2141336152 @default.
• W2968279575 cites W2144719083 @default.
• W2968279575 cites W2151253787 @default.
• W2968279575 cites W2155957543 @default.
• W2968279575 cites W2157923000 @default.
• W2968279575 cites W2165480504 @default.
• W2968279575 cites W2168037598 @default.
• W2968279575 cites W2235523093 @default.
• W2968279575 cites W2517264983 @default.
• W2968279575 cites W2557643461 @default.
• W2968279575 cites W2592734850 @default.
• W2968279575 cites W2611297475 @default.
• W2968279575 cites W2750574597 @default.
• W2968279575 cites W2762043247 @default.
• W2968279575 cites W2771057425 @default.
• W2968279575 cites W2775990711 @default.
• W2968279575 doi "https://doi.org/10.1158/1535-7163.mct-18-1011" @default.
• W2968279575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6825557" @default.
• W2968279575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31395684" @default.
• W2968279575 hasPublicationYear "2019" @default.
• W2968279575 type Work @default.
• W2968279575 sameAs 2968279575 @default.
• W2968279575 citedByCount "11" @default.
• W2968279575 countsByYear W29682795752020 @default.
• W2968279575 countsByYear W29682795752021 @default.
• W2968279575 countsByYear W29682795752022 @default.
• W2968279575 countsByYear W29682795752023 @default.
• W2968279575 crossrefType "journal-article" @default.
• W2968279575 hasAuthorship W2968279575A5002699549 @default.
• W2968279575 hasAuthorship W2968279575A5014278257 @default.
• W2968279575 hasAuthorship W2968279575A5021784750 @default.
• W2968279575 hasAuthorship W2968279575A5023766610 @default.
• W2968279575 hasAuthorship W2968279575A5028439777 @default.
• W2968279575 hasAuthorship W2968279575A5029334844 @default.
• W2968279575 hasAuthorship W2968279575A5042175883 @default.
• W2968279575 hasAuthorship W2968279575A5046463254 @default.
• W2968279575 hasAuthorship W2968279575A5065979183 @default.
• W2968279575 hasAuthorship W2968279575A5069062997 @default.
• W2968279575 hasAuthorship W2968279575A5069758017 @default.
• W2968279575 hasAuthorship W2968279575A5075736599 @default.
• W2968279575 hasAuthorship W2968279575A5076591186 @default.
• W2968279575 hasAuthorship W2968279575A5082550776 @default.
• W2968279575 hasAuthorship W2968279575A5083662386 @default.

• next